Retatrutide Phase 3 Trials: What We Know

Retatrutide completed a phase 3 trial in adults with obesity, published in 2026 in the New England Journal of Medicine by Jastreboff et al., after a phase 2 trial had already shown a dose-dependent reduction in body weight over 48 weeks. That is the headline: retatrutide has moved from an exploratory study into a larger, longer trial, the step the FDA requires before any approval decision is even on the table.

What Retatrutide Is and Why It Reached Phase 3

Retatrutide is a triple agonist: it acts on the GLP-1, GIP, and glucagon receptors at the same time, unlike semaglutide — the molecule behind Ozempic and Wegovy — which activates GLP-1 alone, or tirzepatide — the molecule behind Mounjaro and Zepbound — which combines GLP-1 and GIP. That third pathway, the glucagon receptor, is what sets the molecule apart and what investigators have been studying since phase 2 to see whether it adds a metabolic effect beyond what the two-receptor drugs already produce.

The compound is being developed by a private pharmaceutical company and moves through the same stages any new drug does in the United States: phase 1 for safety and dosing, phase 2 for preliminary efficacy, and phase 3 to confirm the effect in a larger population over a longer period. As of the most recent publication, retatrutide sits in phase 3.

What the Phase 2 Trials Showed First

The phase 2 trial in adults with obesity, published by Jastreboff et al. in NEJM (2023), followed participants for 48 weeks across several weekly doses of injectable retatrutide, compared against placebo. The trial tracked the change in body weight and a set of secondary metabolic markers over the course of treatment, and found a weight reduction that grew with the dose — the pattern that, in this kind of program, is what justifies moving to a phase 3 trial with more participants.

In parallel, Rosenstock et al. published in The Lancet (2023) a separate phase 2 trial in people with type 2 diabetes, evaluating retatrutide's effect on glycemic control in addition to body weight. These are two distinct populations — obesity without diabetes, and type 2 diabetes — and they should not be collapsed into one: each trial had a different primary endpoint.

What the Phase 3 Trial Specifically Evaluated

The phase 3 trial in obesity, reported by Jastreboff et al. in NEJM (2026), scaled up the phase 2 design to a larger sample and a longer follow-up, with the goal of confirming whether the dose-dependent effect seen earlier held in a more diverse population and over more time on the drug. That is exactly what a phase 3 trial is for: not to discover a new effect, but to stress-test the one already observed under conditions closer to real-world use, across more research sites and more variability between participants.

To follow the status of the different arms of this research program — including the ones still recruiting or in progress in other populations — the public reference registry is ClinicalTrials.gov, where every retatrutide trial is listed with its phase, design, and current recruitment status.

Molecule vs. Product: A Distinction Worth Keeping Straight

It is easy to read "not approved" and assume no drug in this class has reached the market, which is not the case. Tirzepatide and semaglutide, as molecules, are approved — under the brand names Mounjaro, Zepbound, Ozempic, and Wegovy — for type 2 diabetes and chronic weight management, as the SURMOUNT-1 and STEP 1 trials and the FDA's own approval announcement document. Retatrutide has not gone through that process. It is a molecule still in phase 3, with no branded product and no FDA decision attached to it yet. The FDA has separately warned about unapproved and compounded GLP-1 products sold for weight loss, which is a different issue from a molecule's trial phase but worth knowing if you are trying to make sense of what "approved" actually covers.

Where Things Stand for FDA Approval

No compound discussed in this post has been approved by the FDA. Reaching phase 3 means the pivotal trial has been reported, but an approval also requires the agency to review the full regulatory dossier, the manufacturing process, and long-term safety data before authorizing a branded drug for sale. Until that happens, retatrutide remains a molecule under investigation, not an approved medication for clinical use.

Finding Retatrutide Today

PeptoClinic supplies retatrutide as a lyophilized powder vial, with an independent laboratory report for every batch. Each report we publish comes from the same outside laboratory, Janoshik Analytical, which tests the purity of every batch — that is how a label gets verified, instead of taking a supplier's word for it. You can see how we read a certificate of analysis at /en/quality/, and pricing by market is published at /en/pricing/.